Sexual functioning is generally impaired during depression. Interest in the relationship between sexual dysfunction and depression has risen substantially, prompted primarily by 1) the 1998 Food and Drug Administration approval of sildenafil citrate as the first oral therapy of erectile dysfunction, and 2) the widespread clinical use of selective serotonin reuptake inhibitors, which prominently impair orgasm, and possibly libido and arousal. In this paper, we first review the phenomenology of sexual dysfunction and important contributing factors, such as age and illness, and then focus on the clinical assessment and therapeutic interventions used for sexual dysfunction in depressed individuals.
KeywordsMajor Depressive Disorder Erectile Dysfunction Sexual Dysfunction Bupropion Premature Ejaculation
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 1.Basson R, Berman J, Burnett A, et al.: Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol 2000, 163:888–893. The report of an international, multidisciplinary consensus development conference that was held in the United States to develop a new classification system to apply to all forms of FSD, regardless of etiology. Major categories of FSD include desire disorders, arousal disorders, orgasm disorders, and sexual pain problems.PubMedCrossRefGoogle Scholar
- 3.Laumann EO, Paik A, Rosen RC: Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999, 281:537–544. Summary report and reanalysis of the National Health and Social Life Survey, the most comprehensive national study of sexual behavior in the United States since Kinsey.PubMedCrossRefGoogle Scholar
- 9.Basson R, McInnes R, Smith MD, et al.: Efficacy and safety of sildenafil in estrogenized women with sexual dysfunction associated with female sexual arousal disorder. Obstet Gynecol 2000, 95:S54. Describes a recent negative study of sildenafil for women with FSD. It is notable for the large N, placebo arm, and strong negative result (see Clinical Trials Report).CrossRefGoogle Scholar
- 12.Heiman JR, Meston CM: Empirically validated treatment for sexual dysfunction. Annu Rev Sex Res 1997, 8:148-94.:148–194.Google Scholar
- 18.Araujo AB, Durante R, Feldman HA, et al.: The relationship between depressive symptoms and male erectile dysfunction: Cross sectional results from the Massachusetts Male Aging Study. Psychosom Med 1998, 60:458–465. This is an important report that uses a large, representative epidemiologic sample to confirm the strong association between self-reported depressive symptoms and ED. Although it cannot address causality, it is the first study to suggest that depression is a risk factor for ED of equal magnitude to the more commonly acknowledged factors, such as cardiovascular morbidity and diabetes.PubMedGoogle Scholar
- 30.Seidman SN, Araujo AB, Roose SP, et al.: Low testosterone levels in elderly men with dysthymic disorder. Am J Psychiatry 2001, in press.Google Scholar
- 45.Michelson D, Bancroft J, Targum S, et al.: Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled study of pharmacologic intervention. Am J Psychiatry 2000, 157:239–243. An important, well-designed, placebo-controlled clinical trial that failed to distinguish between buspirone, amantadine, and placebo in women with fluoxetine-induced sexual dysfunction.PubMedCrossRefGoogle Scholar
- 47.Seidman SN, Roose SP, Shabsigh R, et al.: Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. Am J Psychiatry 2001, in press. A study in which men with depression and ED were randomized to receive sildenafil or placebo. Of particular importance was the finding that men who had an improvement in ED, whether they received sildenafil or placebo, had a substantial improvement in depression.Google Scholar